PD 123319

PD123319 shows inhibition potency in both rat adrenal and brain binding assay with IC50 values of 34nM and 210nM. At high concentrations PD123319 blocks the beneficial effects of the AT2-agonist LP2-3 on RVH. At low concentrations PD123319 attenuates cardiopulmonary injury by reducing pulmonary inflammation and fibrosis and preventing PAH-induced RVH but does not affect alveolar and vascular development in newborn rats with experimental BPD. Administration of PD123319 can suppress the generation of cyclic guanosine monophosphate and increase the production of prostaglandin E2. Besides that, administration of PD-123319 does not in?uence the effect of Ang II on protein tyrosine phosphorylation or thymidine incorporation.

(S)-(+)-PD 123319

C31H32N4O3

>98%